Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy

Romiplostim can improve platelet counts in about 50% of patients with low‐ or intermediate 1‐risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long‐term toxicity and efficacy are not known. This open‐label extension study evaluated the long‐term safety and efficacy of r...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Haematol
Autori principali: Fenaux, Pierre, Muus, Petra, Kantarjian, Hagop, Lyons, Roger M., Larson, Richard A., Sekeres, Mikkael A., Becker, Pamela S., Orejudos, Amelia, Franklin, Janet
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Haematological Malignancy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600084/
https://ncbi.nlm.nih.gov/pubmed/28616874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14792
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi